Tue Sep 17 05:41:17 UTC 2024: ## Genocea Biosciences Outperforms BioAtla in Key Metrics, Despite Bankruptcy Filing

**San Diego, CA & Cambridge, MA – September 17, 2024** – MarketBeat News today compared the performance of two small-cap medical companies, BioAtla (NASDAQ:BCAB) and Genocea Biosciences (NASDAQ:GNCA). Despite Genocea’s recent Chapter 11 bankruptcy filing, the company emerged as the stronger performer across several key metrics.

Genocea boasts higher revenue and earnings than BioAtla. While BioAtla trades at a lower price-to-earnings ratio, indicating a potentially better value, Genocea’s stock is more volatile, with a beta of 1.61 compared to BioAtla’s 1.06.

MarketBeat analysts currently assign BioAtla a consensus price target of $8.67, suggesting a potential upside of 415.87%. Institutional investors hold a significant 77.2% stake in BioAtla, indicating confidence in its future growth. However, Genocea’s institutional ownership is significantly lower at 0.6%.

Overall, Genocea Biosciences outperforms BioAtla in 6 out of 10 factors, despite its bankruptcy. BioAtla, a clinical-stage biopharmaceutical company, focuses on developing antibody-based cancer therapies, while Genocea develops cancer immunotherapies utilizing its proprietary ATLAS platform.

Investors should consider these factors and weigh the risks associated with each company before making investment decisions. While Genocea’s bankruptcy may present challenges, its strong performance across multiple metrics could make it a compelling investment opportunity for those willing to take on greater risk.

Read More